Press Releases
March 4, 2021
Tags | Product
Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C
March 3, 2021
Tags | Product
- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a
February 26, 2021
Tags | Product
INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received
February 25, 2021
Tags | Product
COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.
February 17, 2021
Tags | Product
In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent) INDIANAPOLIS , Feb. 17, 2021 /PRNewswire/ -- Tirzepatide led to significant A1C and body weight reductions from
February 9, 2021
Tags | Product
- Bamlanivimab and etesevimab administered together authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 - More than 250,000 doses manufactured throughout Q1 2021; up to 1 million doses by mid-2021 - FDA
January 27, 2021
Tags | Product
INDIANAPOLIS and SAN FRANCISCO and LONDON , Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with
January 26, 2021
Tags | Product
- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and
January 21, 2021
Tags | Product
INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in
January 11, 2021
Tags | Product
RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death